New EU Fee System To Give Pharma Firms More Predictability
Executive Summary
The publication of a draft EU Regulation governing the fees paid by the pharmaceutical industry to the European Medicines Agency is the latest step in a long process aimed at ensuring that the payment system better reflects the actual costs of the regulatory work carried out or coordinated by the EU regulator.
You may also be interested in...
Swedish EU Presidency Promises Action On Pharma Law Revision, EMA Fees & AMR
Health care and medicines are among the priorities outlined by the new presidency of the Council of the EU for the first half of 2023.
EMA Raises Industry Fees For EU Pharmacovigilance Services
Companies using the European Medicines Agency’s drug safety services will be paying more from 3 October.
EMA Hikes Pharma Industry Fees
This year’s new fee structure at the EMA takes account of the inflation rates in 2020 and 2021 and includes changes relating to inspections and companion diagnostics.